4basebio hpDNA in Genezen projects could cut AAV input DNA by 30%

Genezen, a viral vector contract development and manufacturing organization, is now offering 4basebio’s cell-free synthetic DNA as a selectable starting material inside its viral vector development and manufacturing services. The expanded, non-exclusive collaboration was announced Aug. 26 and is intended to cover work from early development through clinical and commercial manufacturing, according to BioPharm International and a company release distributed by PR Newswire.

The operational hook is a specific materials claim: in AAV production, 4basebio says its hpDNA template has demonstrated comparable titers to plasmid DNA while requiring about 30% less DNA mass and transfection reagent, per PR Newswire. For manufacturing leaders who live in bills of materials and schedule risk, that number is the difference between a “nice platform story” and something that belongs in current process characterization plans.

Why synthetic, cell-free DNA shows up as a CDMO option now

Viral vector teams have spent the last decade squeezing incremental gains out of upstream expression and downstream purification, but starting materials have become the next lever. BioPharm International describes 4basebio’s approach as enzymatic and cell-free, removing bacterial backbone sequences and antibiotic resistance genes that are inherent to conventional plasmid DNA manufacturing.

Those design attributes map directly to day-to-day manufacturing requirements: fewer bacterial-associated impurities to chase, fewer residuals narratives to build, and potentially faster iteration when a construct changes. PR Newswire adds the second lever that tends to matter more at scale, the possibility of reducing input DNA and transfection reagent consumption by roughly 30% in AAV runs while holding titer, which would affect both cost and supply risk for consumables.

What changes for CMC, tech transfer, and procurement teams

For operators, the immediate implication is that “plasmid DNA” is no longer the default line item to carry unchanged from preclinical work into GMP planning. The collaboration makes hpDNA available in Research Use Only, High-Quality, and GMP-grade formats through Genezen’s service stack, according to BioPharm International, which means teams can evaluate the template decision earlier and avoid a late-phase starting-material switch.

Non-exclusive also matters. It signals hpDNA is being positioned as an option that can be written into specifications and quality agreements without locking a program into a single manufacturing partner. That is useful for developers that want dual pathways: keeping plasmid DNA as a comparability baseline while qualifying a cell-free template as a second source or as a later lifecycle change, depending on clinical and commercial timelines.

The work for CMC leaders is in comparability and control strategy, not marketing. BioPharm International frames the cell-free process as eliminating bacterial backbone and antibiotic resistance elements. If a program changes the template, the “what stays the same” list has to be nailed down, titer and full-to-empty ratios, impurity profiles, residual host cell DNA, and any shift in transfection conditions that could alter downstream clearance behavior.

Under the hood: 4basebio’s TruePrime and what it implies for supply

Financial Times’ company description provides a useful sanity check on what 4basebio is selling operationally: synthetic DNA produced via an enzymatic, cell-free process, with primer-free amplification technology it calls TruePrime. FT describes TruePrime as combining two enzymes to achieve isothermal multiple displacement DNA amplification in a continuous cell-free process.

Whether or not a developer cares about the enzymology, the supply-chain takeaway is straightforward. A cell-free DNA supply model shifts the risk profile away from bacterial fermentation steps like master cell banks and antibiotic selection, and toward enzymatic inputs, reaction controls, and analytical release of long DNA constructs. That doesn’t eliminate qualification work, it changes which failure modes procurement and quality should interrogate during vendor assessment.

Where this lands in 2026 manufacturing plans

For Genezen clients, the collaboration is a signal that CDMOs are starting to bundle upstream “templates and transfection” decisions into service offerings, instead of assuming the sponsor arrives with plasmids and a frozen playbook. For 4basebio, it places its hpDNA in a workflow buyers already use, with Genezen acting as the integration layer between template supply and vector production execution, per the BioPharm International and PR Newswire coverage.

The most practical next step for teams evaluating hpDNA is to translate the press-release claim into acceptance criteria. “Comparable titers” is not a universal metric, it depends on cell line, plasmid ratios, helper functions, and transfection method. Programs that run tight on transfection capacity, or that are sensitive to reagent allocation and lot-to-lot behavior, are likely to feel the benefit sooner than programs where downstream yield is the dominant constraint.

Questions to put into your next viral vector SOW and change-control plan

• For AAV runs, what is the measured delta in input DNA mass and transfection reagent at the same target titer when using hpDNA vs plasmid DNA, and what cell line and transfection method was used to generate that data (align this with PR Newswire’s ~30% benchmark)?
• If the template switches, which comparability endpoints will Genezen propose as “must-match” (titer, full-to-empty, impurity profile), and which are treated as process re-optimization variables that could change tech transfer timing?
• What does the quality package look like across RUO, High-Quality, and GMP-grade hpDNA in the Genezen offering, and how are lot genealogy and release testing documented for audits (tie this to BioPharm International’s description of use across development stages)?
• Which supply risks move upstream with a cell-free process, for example enzyme sourcing or reaction controls, and how are they addressed in supplier qualification and continuity planning (use FT’s TruePrime description to frame the discussion)?